Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
January 03 2019 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, announced today that the
company completed enrollment in the first cohort for its Phase 1
dose escalation clinical trial of JTX-4014 as monotherapy in
patients with solid tumors. JTX-4014 is a fully human IgG4
monoclonal antibody designed to specifically bind to PD-1 and block
its interaction with its ligands, PD-L1 and PD-L2, to augment
anti-tumor T cell activity. Jounce is developing JTX-4014 for
potential use in combination with its pipeline of future product
candidates.
“We believe combination therapy will be the mainstay of cancer
immunotherapy treatment and that PD-1 checkpoint inhibitors like
JTX-4014 will be an important component of future regimens,” said
Elizabeth Trehu, M.D., chief medical officer of Jounce
Therapeutics. “As we continue to build and progress our
immunotherapy pipeline, including macrophage and other cold tumor
target treatments, we believe it is important for us to have our
own PD-1 inhibitor to potentially combine with these novel
agents.”
The purpose of this study is to evaluate the safety,
tolerability, and pharmacokinetics and to identify the recommended
Phase 2 dose of JTX-4014 monotherapy in patients with advanced
solid tumors. For more information on this trial, please visit
https://clinicaltrials.gov (Identifier: NCT03790488).
About JTX-4014JTX-4014 is a well-characterized
fully human IgG4 monoclonal antibody designed to block binding to
PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in
combination with its pipeline of future product candidates.
JTX-4014 is currently in Phase 1 clinical development.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within the
human tumor microenvironment (TME) to prioritize targets, and then
identifies related biomarkers designed to match the right
immunotherapy to the right patient. Jounce has three development
stage programs: its two clinical product candidates, JTX-2011, a
monoclonal antibody that binds to and activates ICOS, and JTX-4014,
a monoclonal antibody that binds to PD-1 to be used in combination
with its pipeline of future product candidates, and JTX-8064, a
monoclonal antibody that binds to Leukocyte Immunoglobulin Like
Receptor B2 (LILRB2) that is currently in the IND-enabling phase.
For more information, please visit www.jouncetx.com.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Gina Nugent The Yates Network
(617) 460-3579 gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024